Dermira, Inc. announced that detailed primary results of its Phase 2b study of lebrikizumab in patients with moderate-to-severe atopic dermatitis will be reported at the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV, October 17-20, 2019. In addition, the company will host a conference call and webcast on October 17, 2019, during which Dr. April W. Armstrong will discuss the data presented and company management will provide an overview of the lebrikizumab Phase 3 clinical development program.
“As a prevalent, debilitating condition with limited treatment options, moderate-to-severe atopic dermatitis remains a significant, unmet medical need,” said Tom Wiggans, chairman and chief executive officer at Dermira. “This year, we have made tremendous strides in our commitment to help address this need, producing Phase 2b results that support our belief that lebrikizumab can be a best-in-disease treatment option for the more than 10 million Americans who suffer with this condition, and rapidly advancing the program into Phase 3 development. We look forward to sharing more details about these exciting results and the program we have designed to deliver what we believe will be an important, new therapy to atopic dermatitis patients and the healthcare professionals who care for them.”